Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease
Publication Year: 2024 Source: Value Health PMID: 38843977 DOI: 10.1016/j.jval.2024.05.019
OBJECTIVES: To evaluate content validity and psychometric properties of the 29-item Patient-Reported Outcomes Measurement Information System (PROMIS-29) to determine its suitability in inflammatory bowel disease (IBD) clinical trials. METHODS: Content validity of PROMIS-29 was evaluated using qualitative interviews, including concept elicitation and cognitive debriefing, among patients living with Crohn's disease …
Atopic dermatitis may not confer clinically meaningful risk of inflammatory bowel disease or renal malignancy
Publication Year: 2024 Source: J Am Acad Dermatol PMID: 38844010
No Abstract
Gallic acid attenuates murine ulcerative colitis by promoting group 3 innate lymphocytes, affecting gut microbiota, and bile acid metabolism
Publication Year: 2024 Source: J Nutr Biochem PMID: 38844081
No Abstract
Lipocalin-2-mediated intestinal epithelial cells pyroptosis via NF-κB/NLRP3/GSDMD signaling axis adversely affects inflammation in colitis
Publication Year: 2024 Source: Biochim Biophys Acta Mol Basis Dis PMID: 38844113 DOI: 10.1016/j.bbadis.2024.167279
Ulcerative colitis (UC) is a major inflammatory bowel disease (IBD) characterized by intestinal epithelium damage. Recently, Lipocalin-2 (LCN2) has been identified as a potential fecal biomarker for patients with UC. However, further investigation is required to explore its pro-inflammatory role in UC and the underlying mechanism. The biological analysis revealed …
IL-23 exerts dominant pathogenic functions in Crohn's disease-ileitis
Publication Year: 2024 Source: Mucosal Immunol PMID: 38844209 DOI: 10.1016/j.mucimm.2024.05.008
Crohn's disease (CD), a main form of Inflammatory Bowel Disease (IBD) is a chronic inflammatory disorder, mainly affecting the ileum. Interleukin (IL)-12 and IL-23 are both targeted by Ustekinumab, a commonly used monoclonal antibody for IBD treatment. However, their specific roles in ileitis have not been extensively explored. Here, we …
Provider Specialization in Inflammatory Bowel Diseases: Quality of Care and Outcomes
Publication Year: 2024 Source: Clin Gastroenterol Hepatol PMID: 38844254 DOI: 10.1016/j.cgh.2024.05.024
BACKGROUND & AIMS: Management of inflammatory bowel diseases (IBD) is complex and variation in care has been well-documented. However, the drivers of practice variation remain unexplored. We examined variation based on the treating gastroenterologist's IBD focus (proportion of outpatient visits for IBD). METHODS: We conducted a retrospective cohort of newly …
Downregulation of OATP2B1 by proinflammatory cytokines leads to 5-ASA hyposensitivity in Ulcerative colitis
Publication Year: 2024 Source: Chem Biol Interact PMID: 38844255
No Abstract
Comparison of the value of adipose tissues in abdomen and lumbar vertebra for predicting disease activity in Crohn's disease: A preliminary study based on CSE-MRI
Publication Year: 2024 Source: Magn Reson Imaging PMID: 38844268
No Abstract
Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models
Publication Year: 2024 Source: Br J Clin Pharmacol PMID: 38845210 DOI: 10.1111/bcp.16126
AIMS: Use of infliximab (IFX) has improved outcomes in children with inflammatory bowel disease (IBD). However, a proportion of patients does not respond to IFX or loses response over time. Population pharmacokinetic (PopPK) modelling is a promising approach for IFX dose optimization, but with the increasing number of PopPK models …
Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach
Publication Year: 2024 Source: Drug Dev Res PMID: 38845229
No Abstract
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide